Activator of G-protein signaling 8 is involved in VEGF-induced choroidal neovascularization

[1]  A. Al Mamun,et al.  VEGFR‐3 signaling is regulated by a G‐protein activator, activator of G‐protein signaling 8, in lymphatic endothelial cells , 2018, Experimental cell research.

[2]  Wei Wang,et al.  Diabetic Retinopathy: Pathophysiology and Treatments , 2018, International journal of molecular sciences.

[3]  D. Angoulvant,et al.  Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Medication Use , 2018, JAMA ophthalmology.

[4]  Xiuzhen Han,et al.  Anti-neovascularization effects of DMBT in age-related macular degeneration by inhibition of VEGF secretion through ROS-dependent signaling pathway , 2018, Molecular and Cellular Biochemistry.

[5]  Ofra Benny,et al.  Evolving multidimensional pharmacological approaches to CNV therapy in AMD , 2018, Current eye research.

[6]  E. Zenteno,et al.  Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD , 2018, Oxidative medicine and cellular longevity.

[7]  Yifan Feng,et al.  miR‐539‐5p inhibits experimental choroidal neovascularization by targeting CXCR7 , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  W. Suh,et al.  Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice. , 2017, Investigative ophthalmology & visual science.

[9]  J. Bae,et al.  Intravitreal itraconazole inhibits laser-induced choroidal neovascularization in rats , 2017, PloS one.

[10]  SchnabolkGloriane,et al.  New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement. , 2017 .

[11]  H. Peshavariya,et al.  miR-126 Regulation of Angiogenesis in Age-Related Macular Degeneration in CNV Mouse Model , 2016, International journal of molecular sciences.

[12]  A. Al Mamun,et al.  Activator of G-protein signaling 8 is involved in VEGF-mediated signal processing during angiogenesis , 2016, Journal of Cell Science.

[13]  K. Freund,et al.  Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration , 2015, Clinical ophthalmology.

[14]  B. Rohrer,et al.  New insights on complement inhibitor CD59 in mouse laser-induced choroidal neovascularization: reduced expression after injury and targeted delivery for protein replacement , 2015 .

[15]  J. Gutkind,et al.  Novel insights into G protein and G protein-coupled receptor signaling in cancer. , 2014, Current opinion in cell biology.

[16]  Abdullah Al Mamun,et al.  Protection of Cardiomyocytes from the Hypoxia-Mediated Injury by a Peptide Targeting the Activator of G-Protein Signaling 8 , 2014, PloS one.

[17]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[18]  B. Yaspan,et al.  Mechanisms of age‐related macular degeneration and therapeutic opportunities , 2014, The Journal of pathology.

[19]  J. Rakic,et al.  Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice , 2013, Nature Protocols.

[20]  Motohiko Sato.  Roles of accessory proteins for heterotrimeric G-protein in the development of cardiovascular diseases. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[21]  Lois E. H. Smith,et al.  Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis , 2013, PloS one.

[22]  J. Ambati,et al.  Mechanisms of Age-Related Macular Degeneration , 2012, Neuron.

[23]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[24]  John C Chappell,et al.  Regulation of blood vessel sprouting. , 2011, Seminars in cell & developmental biology.

[25]  Yuan-Yuan Shi,et al.  Influence of Dll4 via HIF-1α-VEGF Signaling on the Angiogenesis of Choroidal Neovascularization under Hypoxic Conditions , 2011, PloS one.

[26]  S. Okumura,et al.  Identification of Transcription Factor E3 (TFE3) as a Receptor-independent Activator of Gα16 , 2011, The Journal of Biological Chemistry.

[27]  S. Harding,et al.  Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. , 2011, Current drug targets.

[28]  R. Dermietzel,et al.  Non-viral siRNA delivery into the mouse retina in vivo , 2010, BMC ophthalmology.

[29]  A. Prota,et al.  Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. , 2010, Biochimica et biophysica acta.

[30]  T. Honda,et al.  Activator of G Protein Signaling 8 (AGS8) Is Required for Hypoxia-induced Apoptosis of Cardiomyocytes , 2009, The Journal of Biological Chemistry.

[31]  J. Ruiz-Moreno,et al.  Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. , 2009, Survey of ophthalmology.

[32]  H. Dvorak,et al.  VEGF-A and the induction of pathological angiogenesis. , 2007, Annual review of pathology.

[33]  W. Chilian,et al.  Identification of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gbetagamma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Cunningham,et al.  Managing Patients Treated with Bevacizumab Combination Therapy , 2005, Oncology.

[35]  F. Hu,et al.  Specific antigen and organelle expression of a long-term rhesus endothelial cell line , 1987, In Vitro Cellular & Developmental Biology.

[36]  Ivana K. Kim,et al.  Clinical characteristics and current treatment of age-related macular degeneration. , 2014, Cold Spring Harbor perspectives in medicine.

[37]  Robert S Kerbel.  Tumor angiogenesis. , 2008, The New England journal of medicine.

[38]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[39]  J. Wood,et al.  Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors , 2004, Cancer and Metastasis Reviews.

[40]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.